Issue Price
₹100
Per Share
GMP
NIL
Grey Market
Est. Listing
₹100
Expected Price
Min. Application
₹12,000
2 lots × 60 shares
Incorporated in 2002, Brooks Laboratories Ltd is in the business of Pharmaceutical Contract Research & Manufacturing. Company manufactures wide range of products catering to critical care segment in Parental Section like Beta Lactam, Cephalosporin & General Dry powder Injectables, Ampoules and Liquid vials, Dry Syrups and Tablets etc.Brooks Labs has manufacturing unit at Baddi, Himachal Pradesh. Company has a world class team to develop new molecules in injectables and clavulanic acid based products supported by sophisticated infrastructure for Research & Development. Brooks Labs is WHO-GMP and ISO 9000-2008 certified company.The Indian pharmaceuticals industry is significantly developed in terms of infrastructure, technology and product range in recent years. The country now ranks among the top four worldwide accounting for 8% to 10% of world’s production by volume and 1.5% to 2% by value.
Brooks Laboratories Ltd. proposes to utilise the net proceeds from the Issue for the following objects:
| Category | Shares Offered | % Issue | Amount (₹ Cr)* | Subscription |
|---|---|---|---|---|
| TOTAL | 6,300,000 | 100.00% | ₹63.00 Cr | — |
| Category | Lots | Shares | Amount (₹) |
|---|---|---|---|
| Retail (Min) | 1 | 60 | ₹6,000 |
| Retail (Max) | 2 | 120 | ₹12,000 |
| sNII (Min) | 34 | 2,040 | ₹204,000 |
| bNII (Min) | 167 | 10,020 | ₹1,002,000 |
| Particulars | 31-Mar-11 | 31-Mar-10 | 31-Mar-09 |
|---|---|---|---|
| Revenue from Operations | 5319.90 | 4545.30 | 4383.20 |
| EBITDA | N/A | N/A | N/A |
| Profit After Tax (PAT) | 688.82 | 519.57 | 296.06 |
| Net Worth | N/A | N/A | N/A |
| Total Assets | N/A | N/A | N/A |
| Reserves & Surplus | N/A | N/A | N/A |
| Total Borrowings | N/A | N/A | N/A |